These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception. Cameron ST; Glasier A; Johnstone A Contraception; 2012 May; 85(5):458-64. PubMed ID: 22079602 [TBL] [Abstract][Full Text] [Related]
5. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density. Kaunitz AM; Darney PD; Ross D; Wolter KD; Speroff L Contraception; 2009 Jul; 80(1):7-17. PubMed ID: 19501210 [TBL] [Abstract][Full Text] [Related]
6. Women's responses to Depo-Provera. Freda MC; Abruzzo-Fogarassy M; Adams NV; Davini D; DeVore N; Merkatz IR MCN Am J Matern Child Nurs; 1996; 21(4):183-6. PubMed ID: 8754434 [No Abstract] [Full Text] [Related]
7. Immunosuppressive biological mechanisms support reassessment of use of the injectable contraceptive medroxyprogesterone acetate. Hapgood JP Endocrinology; 2013 Mar; 154(3):985-8. PubMed ID: 23429710 [No Abstract] [Full Text] [Related]
8. Contraceptive efficacy and safety of DMPA-SC. Jain J; Jakimiuk AJ; Bode FR; Ross D; Kaunitz AM Contraception; 2004 Oct; 70(4):269-75. PubMed ID: 15451329 [TBL] [Abstract][Full Text] [Related]
11. The use of depot medroxyprogesterone acetate (DMPA) injectable contraceptive in Enugu, Nigeria. Hu E; Ikeako LC; Obiora-Okafor NC Niger J Med; 2012; 21(3):266-71. PubMed ID: 23304918 [TBL] [Abstract][Full Text] [Related]
12. Depo Provera. Position paper on clinical use, effectiveness and side effects. Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658 [TBL] [Abstract][Full Text] [Related]
13. Depot medroxyprogesterone acetate contraceptive injections and skeletal health. Renner RM; Edelman AB; Kaunitz AM Womens Health (Lond); 2010 May; 6(3):339-42. PubMed ID: 20426597 [No Abstract] [Full Text] [Related]
15. Painless Depo-medroxyprogesterone acetate (DMPA) injections using the 'pinch technique'. Fletcher H J Obstet Gynaecol; 2004 Aug; 24(5):562-3. PubMed ID: 15369941 [TBL] [Abstract][Full Text] [Related]
16. The acceptability of self-administration of subcutaneous Depo-Provera. Lakha F; Henderson C; Glasier A Contraception; 2005 Jul; 72(1):14-8. PubMed ID: 15964286 [TBL] [Abstract][Full Text] [Related]
17. Accounting for anovulation and vaginal thinning during depot medroxyprogesterone acetate use. Atrio J J Infect Dis; 2015 Mar; 211(5):850. PubMed ID: 25217405 [No Abstract] [Full Text] [Related]
18. Preference for Sayana® Press versus intramuscular Depo-Provera among HIV-positive women in Rakai, Uganda: a randomized crossover trial. Polis CB; Nakigozi GF; Nakawooya H; Mondo G; Makumbi F; Gray RH; Contraception; 2014 May; 89(5):385-95. PubMed ID: 24332432 [TBL] [Abstract][Full Text] [Related]
19. Contraception 2000: lunelle, an injectable combination contraceptive option. Shulman LP J Womens Health Gend Based Med; 2000 Sep; 9(7):725-9. PubMed ID: 11025864 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and acceptability of depo-medroxyprogesterone acetate injection. As a method of contraception in Saudi Arabia. Sobande AA; Al-Bar HM; Archibong EI; Sadek AA Saudi Med J; 2000 Apr; 21(4):348-51. PubMed ID: 11533816 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]